Why is careful management of anticoagulation important in the context of CABG autotransfusion?

• A. Autotransfusion has no effect
• B. Autotransfusion can affect coagulation; balancing heparin and protamine with careful monitoring helps prevent bleeding or thrombosis
• C. Anticoagulation is not used after CABG
• D. Auto transfusion only affects platelets

Answer: (B)

In this scenario, the important idea is that the way we manage anticoagulation directly affects how well blood clotting can occur after using autotransfusion. During CABG, heparin is given to prevent clotting in the bypass circuit. After coming off bypass, protamine is given to reverse that heparin and restore normal coagulation. The blood that’s salvaged and reinfused from the surgical field—often washed by a cell-saver device—can still contain residual heparin, as well as altered platelets and clotting factors from CPB. Reinfusing this blood can shift the patient’s coagulation balance in ways that either increase bleeding risk (if residual heparin remains and isn’t fully neutralized) or promote thrombosis (if anticoagulation is overcorrected or if platelets are not adequately restored).

That’s why careful tuning of heparin and protamine, guided by monitoring of coagulation status (like ACT or more advanced tests if available), is essential when autotransfusion is used. The goal is to neutralize any residual anticoagulant without tipping too far to the other side, which could worsen bleeding or provoke clotting. Autotransfusion can help by reintroducing platelets and coagulation factors, but the overall effect depends on precise anticoagulation management and vigilant monitoring throughout and after the reinfusion.